RS60316B1 - Lečenje dijabetesa tipa 1 korišćenjem glp-1 i anti-il-21 - Google Patents

Lečenje dijabetesa tipa 1 korišćenjem glp-1 i anti-il-21

Info

Publication number
RS60316B1
RS60316B1 RS20200580A RSP20200580A RS60316B1 RS 60316 B1 RS60316 B1 RS 60316B1 RS 20200580 A RS20200580 A RS 20200580A RS P20200580 A RSP20200580 A RS P20200580A RS 60316 B1 RS60316 B1 RS 60316B1
Authority
RS
Serbia
Prior art keywords
glp
treatment
diabetes type
diabetes
type
Prior art date
Application number
RS20200580A
Other languages
English (en)
Inventor
Ken Coppieters
Herrath Matthias Von
Tamar Boursalian
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of RS60316B1 publication Critical patent/RS60316B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RS20200580A 2014-05-07 2015-05-05 Lečenje dijabetesa tipa 1 korišćenjem glp-1 i anti-il-21 RS60316B1 (sr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461989841P 2014-05-07 2014-05-07
EP14169596 2014-05-23
EP14189732 2014-10-21
PCT/EP2015/059811 WO2015169789A1 (en) 2014-05-07 2015-05-05 Treatment of diabetes type 1 using glp-1 and anti-il-21
EP15720982.6A EP3139948B1 (en) 2014-05-07 2015-05-05 Treatment of diabetes type 1 using glp-1 and anti-il-21

Publications (1)

Publication Number Publication Date
RS60316B1 true RS60316B1 (sr) 2020-07-31

Family

ID=54392180

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20200580A RS60316B1 (sr) 2014-05-07 2015-05-05 Lečenje dijabetesa tipa 1 korišćenjem glp-1 i anti-il-21

Country Status (9)

Country Link
US (1) US10105442B2 (sr)
EP (1) EP3139948B1 (sr)
JP (1) JP6672175B2 (sr)
CN (1) CN106999553B (sr)
PL (1) PL3139948T3 (sr)
RS (1) RS60316B1 (sr)
SI (1) SI3139948T1 (sr)
TW (1) TWI668010B (sr)
WO (1) WO2015169789A1 (sr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017149109A1 (en) * 2016-03-04 2017-09-08 Novo Nordisk A/S Liraglutide in diabetic foot ulcer
US12012441B2 (en) 2020-10-26 2024-06-18 Neptune Biosciences Llc Engineered human IL-21 cytokines and methods for using the same

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT944648E (pt) 1996-08-30 2007-06-26 Novo Nordisk As Derivados do glp-1.
US7186683B2 (en) 2000-09-18 2007-03-06 Sanos Bioscience A/S Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
JP5562510B2 (ja) * 2001-06-28 2014-07-30 ノヴォ ノルディスク アー／エス 修飾ｇｌｐ−１の安定な処方剤
EP1432431B1 (en) 2001-10-04 2017-05-10 Genetics Institute LLC Methods and compositions for modulating interleukin-21 activity
EP1515749B1 (en) * 2002-06-14 2012-08-15 Novo Nordisk A/S Combined use of a modulator of cd3 and a glp-1 compound
WO2005023291A2 (en) * 2003-09-11 2005-03-17 Novo Nordisk A/S Use of glp1-agonists in the treatment of patients with type i diabetes
CN101380476A (zh) * 2003-09-19 2009-03-11 诺沃挪第克公司 治疗肽的清蛋白结合型衍生物
EP2298337B1 (en) * 2003-12-09 2017-02-22 Novo Nordisk A/S Regulation of food preference using GLP-1 agonists
EP1841448A2 (en) 2004-12-30 2007-10-10 Diakine Therapeutics, Inc. Pharmaceutical compositions and methods for restoring beta-cell mass and function
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
EP2295066B1 (en) 2005-05-25 2016-04-27 CureDM Group Holdings, LLC Peptides, derivatives and analogs thereof, and methods of using same
WO2007005738A2 (en) * 2005-06-30 2007-01-11 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Glp-1 pharmaceutical compositions
US8278420B2 (en) 2005-08-06 2012-10-02 Qinghua Wang Composition and method for prevention and treatment of type I diabetes
HUE064811T2 (hu) * 2005-08-19 2024-04-28 Amylin Pharmaceuticals Llc Extendin diabétesz kezelésében és testtömeg csökkentésében történõ alkalmazásra
CN101291685A (zh) * 2005-08-19 2008-10-22 安米林药品公司 治疗糖尿病和降低体重的毒蜥外泌肽
US8084022B2 (en) * 2006-06-23 2011-12-27 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
BRPI0716134A2 (pt) * 2006-09-07 2013-09-17 Nycomed Gmbh tratamento de combinaÇço para diabetes mellitus
EP2170951A2 (en) * 2007-05-31 2010-04-07 Genmab A/S Recombinant non glycosylated monovalent half-antibodies obtained by molecular engineering
CN101896499B (zh) * 2007-08-30 2014-02-12 库尔Dm股份有限公司 使用前胰岛肽及其类似物的组合物和方法
WO2009030738A1 (en) * 2007-09-05 2009-03-12 Novo Nordisk A/S Glucagon-like peptide-1 derivatives and their pharmaceutical use
CN102027011B (zh) 2007-12-07 2014-09-03 津莫吉尼蒂克斯公司 抗人il-21单克隆抗体
US8999383B2 (en) * 2008-05-07 2015-04-07 Merrion Research Iii Limited Compositions of GnRH related compounds and processes of preparation
EP3412300A1 (en) * 2008-06-27 2018-12-12 Duke University Therapeutic agents comprising elastin-like peptides
PT2498802E (pt) * 2009-11-13 2015-04-13 Sanofi Aventis Deutschland Composição farmacêutica que compreende um agonista de glp-1, uma insulina e metionina
EP2460527A1 (en) * 2010-01-21 2012-06-06 Sanofi Pharmaceutical composition for treating a metabolic syndrome
EP2539470B1 (en) 2010-02-24 2017-02-22 The Board of Trustees of The Leland Stanford Junior University Methods for autoimmune disease diagnosis, prognosis, and treatment
CN103443124A (zh) * 2011-01-17 2013-12-11 诺沃—诺迪斯克有限公司 Il-21配体
RU2650784C2 (ru) * 2011-05-05 2018-04-17 Альбумедикс А/С Варианты альбумина
CN103702721A (zh) * 2011-05-31 2014-04-02 诺沃—诺迪斯克有限公司 Il-21表位和il-21配体
EP2746292A1 (en) 2012-12-21 2014-06-25 Novo Nordisk A/S Anti-IL21 antibodies for use in the treatment of nephropathies
EP2746293A1 (en) 2012-12-21 2014-06-25 Novo Nordisk A/S Anti-IL21 antibodies for use in the treatment of cardiovascular diseases

Also Published As

Publication number Publication date
PL3139948T3 (pl) 2020-08-10
TW201625289A (zh) 2016-07-16
SI3139948T1 (sl) 2020-07-31
US20170043014A1 (en) 2017-02-16
WO2015169789A1 (en) 2015-11-12
EP3139948B1 (en) 2020-03-04
JP6672175B2 (ja) 2020-03-25
EP3139948A1 (en) 2017-03-15
TWI668010B (zh) 2019-08-11
JP2017514860A (ja) 2017-06-08
CN106999553A (zh) 2017-08-01
US10105442B2 (en) 2018-10-23
CN106999553B (zh) 2021-11-26

Similar Documents

Publication Publication Date Title
HRP20190369T1 (hr) Spojevi dihidrobenzofurana koji su korisni u liječenju dijabetesa i pretilosti
HK1243073A1 (zh) 治療性化合物及其用途
IL246757B (en) New insulin histories and their medical uses
HUE057301T2 (hu) Bariátriai eljárást követõ hipoglikémia kezelése GLP-1 antagonistákkal
IL283335B (en) Dihydropyrimidine-2-one compounds and their medical use
HK1244216A1 (zh) 治療2型糖尿病患者
GB201612165D0 (en) Combinations for the treatment of type 2 diabetes
HK1251449A1 (zh) 用於治療2型糖尿病的交聯聚二烯丙基胺共聚物
IL254500A0 (en) Treatment of patients with type 2 diabetes
GB201403996D0 (en) Traditional chinese medicine composition for the treatment of diabetes
PL3139948T3 (pl) Leczenie cukrzycy z zastosowaniem glp-1 i anty-il-21
HK1244821A1 (zh) 用於治療和診斷1型糖尿病中使用的肽
GB201707207D0 (en) Treatment of type 1 diabetes
IL250666B (en) A peptide for the treatment of diabetes mellitus type 2 and its complications
HK1257593A1 (zh) 治療糖尿病的新藥物及其用途
HUE048860T2 (hu) 1-es típusú cukorbetegség kezelése GLP-1 és anti-IL-21 alkalmazásával
GB201513543D0 (en) Compositions for use in the treatment of diabetes
GB201418541D0 (en) Materials for use with general hyperthermia treatment
SG10201400823PA (en) Therapeutic methods and compositions for treating diabetes
GB201417777D0 (en) Novel compounds and therapeutic uses thereof